FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sandrine Marchais-Oberwinkler

Research Profile

Chemicals & Drugs

Concepts & Ideas

Genes & Molecular Sequences

Molecular Structure

Anatomy

Occupations

Drug Design

Living Beings

Rats

Co-author Network

Publications

TOP 3
Sandrine Marchais-Oberwinkler; Arne Meyer; Gabriele Möller; Matthias Negri; Alex Odermatt; Enrico Perspicace; Marie Wetzel; Kuiying Xu; Jerzy Adamski; Rolf W Hartmann
Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis.
Enrico Perspicace; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
Synthesis and Biological Evaluation of Thieno[3,2-d]- pyrimidinones, Thieno[3,2-d]pyrimidines and Quinazolinones: Conformationally Restricted 17b-Hydroxysteroid Dehydrogenase Type 2 (17b-HSD2) Inhibitors.
Yaseen A Al-Soud; Martin Frotscher; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sandrine Marchais-Oberwinkler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sandrine Marchais-Oberwinkler; Arne Meyer; Gabriele Möller; Matthias Negri; Alex Odermatt; Enrico Perspicace; Marie Wetzel; Kuiying Xu; Jerzy Adamski; Rolf W Hartmann
Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis.
Journal of medicinal chemistry 2013;56(1):167-81.
2013: Enrico Perspicace; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
Synthesis and Biological Evaluation of Thieno[3,2-d]- pyrimidinones, Thieno[3,2-d]pyrimidines and Quinazolinones: Conformationally Restricted 17b-Hydroxysteroid Dehydrogenase Type 2 (17b-HSD2) Inhibitors.
Molecules (Basel, Switzerland) 2013;18(4):4487-509.
2012: Yaseen A Al-Soud; Martin Frotscher; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
Archiv der Pharmazie 2012;345(8):610-21.
2012: Claudia Henn; Sandrine Marchais-Oberwinkler; Almuth Einspanier; Martin Frotscher; Rolf W Hartmann
Lead optimization of 17β-HSD1 inhibitors of the (hydroxyphenyl)naphthol sulfonamide type for the treatment of endometriosis.
Journal of medicinal chemistry 2012;55(7):3307-18.
2012: Marie Wetzel; Emanuele M Gargano; Stefan Hinsberger; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis.
European journal of medicinal chemistry 2012;47(1):1-17.
2011: Kuiying Xu; Marie Wetzel; Yaseen A Al-Soud; Rolf W Hartmann; Sandrine Marchais-Oberwinkler
Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
European journal of medicinal chemistry 2011;46(12):5978-90.
2011: Marie Wetzel; Jerzy Adamski; Sandrine Marchais-Oberwinkler; Gabriele Möller; Enrico Perspicace; Rolf W Hartmann
Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors.
Journal of medicinal chemistry 2011;54(21):7547-57.
2011: Sandrine Marchais-Oberwinkler; Claudia Henn; Gabriele Möller; Tobias Klein; Matthias Negri; Alexander Oster; Alessandro Spadaro; Ruth Werth; Marie Wetzel; Kuiying Xu; Martin Frotscher; Rolf W Hartmann; Jerzy Adamski
17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
The Journal of steroid biochemistry and molecular biology 2011;125(1-2):66-82.
2011: Alexander Oster; Tobias Klein; Claudia Henn; Ruth Werth; Sandrine Marchais-Oberwinkler; Martin Frotscher; Rolf W Hartmann
Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
ChemMedChem 2011;6(3):476-87.
2011: Sandrine Marchais-Oberwinkler; Marie Wetzel; Erika Ziegler; Patricia Kruchten; Ruth Werth; Claudia Henn; Rolf W Hartmann; Martin Frotscher
New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.
Journal of medicinal chemistry 2011;54(2):534-47.
2011: Marie Wetzel; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold.
Bioorganic & medicinal chemistry 2011;19(2):807-15.
2010: Alexander Oster; Stefan Hinsberger; Ruth Werth; Sandrine Marchais-Oberwinkler; Martin Frotscher; Rolf W Hartmann
Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.
Journal of medicinal chemistry 2010;53(22):8176-86.
2010: Alexander Oster; Tobias Klein; Ruth Werth; Patricia Kruchten; Emmanuel Bey; Matthias Negri; Sandrine Marchais-Oberwinkler; Martin Frotscher; Rolf W Hartmann
Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
Bioorganic & medicinal chemistry 2010;18(10):3494-505.
2009: Emmanuel Bey; Sandrine Marchais-Oberwinkler; Matthias Negri; Patricia Kruchten; Alexander Oster; Tobias Klein; Alessandro Spadaro; Ruth Werth; Martin Frotscher; Barbara Birk; Rolf W Hartmann
New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
Journal of medicinal chemistry 2009;52(21):6724-43.
2009: Patricia Kruchten; Ruth Werth; Emmanuel Bey; Alexander Oster; Sandrine Marchais-Oberwinkler; Martin Frotscher; Rolf W Hartmann
Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells.
The Journal of steroid biochemistry and molecular biology 2009;114(3-5):200-6.
2009: Patricia Kruchten; Ruth Werth; Sandrine Marchais-Oberwinkler; Martin Frotscher; Rolf W Hartmann
Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
Molecular and cellular endocrinology 2009;301(1-2):154-7.
2009: Sandrine Marchais-Oberwinkler; Martin Frotscher; Erika Ziegler; Ruth Werth; Patricia Kruchten; Josef Messinger; Hubert Thole; Rolf W Hartmann
Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Molecular and cellular endocrinology 2009;301(1-2):205-11.
2009: Yaseen A Al-Soud; Emmanuel Bey; Alexander Oster; Sandrine Marchais-Oberwinkler; Ruth Werth; Patricia Kruchten; Martin Frotscher; Rolf W Hartmann
The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Molecular and cellular endocrinology 2009;301(1-2):212-5.
2008: Emmanuel Bey; Sandrine Marchais-Oberwinkler; Ruth Werth; Matthias Negri; Yaseen A Al-Soud; Patricia Kruchten; Alexander Oster; Martin Frotscher; Barbara Birk; Rolf W Hartmann
Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
Journal of medicinal chemistry 2008;51(21):6725-39.
2008: Sandrine Marchais-Oberwinkler; Patricia Kruchten; Martin Frotscher; Erika Ziegler; Alexander Neugebauer; Umadevi Bhoga; Emmanuel Bey; Ursula Müller-Vieira; Josef Messinger; Hubert Thole; Rolf W Hartmann
Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Journal of medicinal chemistry 2008;51(15):4685-98.
2008: Emmanuel Bey; Sandrine Marchais-Oberwinkler; Patricia Kruchten; Martin Frotscher; Ruth Werth; Alexander Oster; Oztekin Algül; Alexander Neugebauer; Rolf W Hartmann
Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bioorganic & medicinal chemistry 2008;16(12):6423-35.
2008: Martin Frotscher; Erika Ziegler; Sandrine Marchais-Oberwinkler; Patricia Kruchten; Alexander Neugebauer; Ludivine Fetzer; Christiane Scherer; Ursula Müller-Vieira; Josef Messinger; Hubert Thole; Rolf W Hartmann
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Journal of medicinal chemistry 2008;51(7):2158-69.
2006: Marieke Voets; Iris Antes; Christiane Scherer; Ursula Müller-Vieira; Klaus Biemel; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Journal of medicinal chemistry 2006;49(7):2222-31.
2005: Marieke Voets; Iris Antes; Christiane Scherer; Ursula Müller-Vieira; Klaus Biemel; Catherine Barassin; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Journal of medicinal chemistry 2005;48(21):6632-42.
2005: Julie A McCarron; Sandrine Marchais-Oberwinkler; Victor W Pike; Jari Tarkiainen; Christer Halldin; Judit Sóvagó; Balàzs Gulyas; Håkan V Wikström; Lars Farde
Two C-methyl derivatives of [11C]WAY-100635--effects of an amido alpha-methyl group on metabolism and brain 5-HT1A receptor radioligand behavior in monkey.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2005;7(3):209-19.
2005: Sandrine Marchais-Oberwinkler; Bartek Nowicki; Victor W Pike; Christer Halldin; Johan Sandell; Yuan-Hwa Chou; Balazs Gulyas; Lise T Brennum; Lars Farde; Håkan V Wikström
N-oxide analogs of WAY-100635: new high affinity 5-HT(1A) receptor antagonists.
Bioorganic & medicinal chemistry 2005;13(3):883-93.
2004: Marieke Voets; Ursula Müller-Vieira; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
Synthesis of amidinohydrazones and evaluation of their inhibitory effect towards aldosterone synthase (CYP11B2) and the formation of selected steroids.
Archiv der Pharmazie 2004;337(7):411-6.
2004: Julie A McCarron; Victor W Pike; Christer Halldin; Johan Sandell; Judit Sóvágó; Balàsz Gulyas; Zsolt Cselényi; Håkan V Wikström; Sandrine Marchais-Oberwinkler; Bartek Nowicki; Frédéric Dollé; Lars Farde
The pyridinyl-6 position of WAY-100635 as a site for radiofluorination--effect on 5-HT1A receptor radioligand behavior in vivo.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2004;6(1):17-26.